← ANALYST RATINGS · TIPRANKS
Indivior (INDV): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $43.00, the highest $43.00, the lowest $43.00. The average is +32.5% from the last price of $32.45.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $37.00 → $36.00−2.7% | Hold | +10.9% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $38.00 → $37.00−2.6% | Hold | +14.0% | Downgrade | 16.10.26on TipRanks 00:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $37.00 → $36.00−2.7% | Hold | +10.9% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| Chase Knickerbocker★★★★★★★★★★#75 · hits 59% · avg +36.2% | Craig-Hallum | — | Buy | — | Reiterated | 17.09.26on TipRanks Sep 18 07:25 | +2.8%next day −2.4% · 5 days 0.0% | ↗ |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $36.00 → $35.00−2.8% | Hold | +7.9% | Reiterated | 17.09.26on TipRanks 09:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $36.00 → $35.00−2.8% | Hold | +7.9% | Reiterated | 17.09.26on TipRanks 09:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $35.00 | Hold | +7.9% | Reiterated | 17.09.26on TipRanks 09:05 | — | |
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $46.00 → $43.00−6.5% | Buy | +32.5% | Reiterated | 05.08.26on TipRanks 04:13 | +6.3%next day 0.0% · 5 days −0.4% | ↗ |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $48.00 | Buy | +47.9% | Reiterated | 04.08.26on TipRanks 06:24 | −4.1%next day +6.3% · 5 days +5.4% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $54.00 → $59.00+9.3% | Buy | +81.8% | Reiterated | 22.05.26on TipRanks 07:25 | −0.2%next day +0.1% · 5 days −8.8% | ↗ |
| Carl Byrnes★★★★★★★★★★#11765 · hits 37% · avg −4.0% | Northland Securities | $50.00 | Buy | +54.1% | Reiterated | 27.02.26on TipRanks 12:25 | −2.5%next day −2.3% · 5 days +0.6% | ↗ |
| Thibault Boutherin★★★★★★★★★★#3632 · hits 62% · avg +7.0% | Morgan Stanley | $28.00 → $36.00+28.6% | Buy | +10.9% | Reiterated | 03.12.25on TipRanks 08:20 | −0.3%next day +1.6% · 5 days +3.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Indivior
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $45.50 at a price of $35.85 (+26.9%); now: $45.50 at $32.45 (+40.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 0 | 0 | 0 |
| Buy | 2 | 3 | 3 | 5 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.06 (from $0.93 to $1.15). Last quarter: $1.15.
Sales
Next quarter’s sales estimate — $329M (from $327M to $332M). Last quarter: $343M.
Best top-analyst consensus in the sector · Healthcare
About Indivior
- CEO: Joseph J. Ciaffoni
- Employees: 833
- 10710 Midlothian Turnpike, North Chesterfield, VA, 23235, US
- www.indivior.com
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
Data from the stock’s TipRanks forecast page, read 24 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗